Search
Abeona Therapeutics Inc
ABEOAdd to Watchlist
6.420USD
-0.050-0.77%
Close 07-31 16:00（ET）Quotes delayed by 15 min
365.91MMarket Cap
5.00P/E TTM
More Details of Abeona Therapeutics Inc Company
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Abeona Therapeutics Inc Info
Ticker SymbolABEO
Company nameAbeona Therapeutics Inc
IPO dateSep 19, 1980
CEOSeshadri (Vishwas)
Number of employees136
Security typeOrdinary Share
Fiscal year-endSep 19
Address6555 Carnegie Ave, 4th Floor
CityCLEVELAND
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code44103
Phone16468134701
Websitehttps://abeonatherapeutics.com/
Ticker SymbolABEO
IPO dateSep 19, 1980
CEOSeshadri (Vishwas)
Company Executives of Abeona Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.31M
-5.20%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
217.78K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
167.94K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
162.61K
-6.76%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
119.56K
-15.19%
Dr. Bernhardt G. Zeiher, M.D.
Dr. Bernhardt G. Zeiher, M.D.
Independent Director
Independent Director
84.46K
--
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
77.06K
-9.08%
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Director
Independent Director
--
--
Dr. Brendan O Malley, J.D., Ph.D.
Dr. Brendan O Malley, J.D., Ph.D.
General Counsel
General Counsel
--
--
Mr. Joseph Vazzano, CPA
Mr. Joseph Vazzano, CPA
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.31M
-5.20%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
217.78K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
167.94K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
162.61K
-6.76%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
119.56K
-15.19%
Dr. Bernhardt G. Zeiher, M.D.
Dr. Bernhardt G. Zeiher, M.D.
Independent Director
Independent Director
84.46K
--
FAQs
Who are the top five shareholders of Abeona Therapeutics Inc?
The top five shareholders of Abeona Therapeutics Inc are: Dr. Vishwas (Vish) Seshadri, Ph.D.
How many institutions hold shares of Abeona Therapeutics Inc (ABEO)?
As of 2026Q1, 221 institutions hold shares of Abeona Therapeutics Inc, with a combined market value of approximately 40.30M, accounting for 70.85% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -6739269.00.